Saturday 17 October 2026
Export AZTR’s income statement to Excel — free account
Azitra, Inc.
AZTR Healthcare Biotechnology
Azitra, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $7,500.00, down 98.9% from fiscal 2023. In the quarter to June 2026, EPS grew 85.6% and free cash flow fell 19.6%, each against the same quarter a year earlier.
0.07
0.00
0.00%
Follow AZTR
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | — | — | — | 184.00 | 2.53 | 0.26 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | — | — | — | — | 1,036.00 | 456.00 | 4.33 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | — | — | 10 | 10 | 12 | 13 | ||||
| Revenue/emp, $m | — | — | — | — | — | 0.00 | 0.03 | 0.07 | 0.00 | 0.00 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | 0 | 0 | 1 | 0 | — | ||||
| Gross margin, % | — | — | — | — | — | 22.91 | 100.00 | 100.00 | 100.00 | — | |||||
| EBT | — | — | — | — | — | (9) | (11) | (11) | (9) | (11) | |||||
| EBT margin, % | — | — | — | — | — | (8,127.00) | (3,760.70) | (1,642.35) | (119,446.67) | 0.00 | |||||
| Net income | — | — | — | — | — | (9) | (11) | (11) | (9) | (11) | |||||
| Depreciation | — | — | — | — | — | 0 | 0 | 1 | 1 | 0 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | 0.01 | 53.58 | 19.88 | 0.01 | 0.00 | ||||
| Earnings | — | — | — | — | — | (0.97) | (2,023.28) | (326.82) | (15.70) | (2.25) | |||||
| Cash flow | — | — | — | — | — | (0.67) | (1,575.38) | (213.40) | (17.83) | (2.30) | |||||
| Capex | — | — | — | — | — | 0.00 | (63.55) | (9.23) | (0.66) | (0.04) | |||||
| Free cash flow | — | — | — | — | — | (0.67) | (1,638.92) | (222.63) | (18.49) | (2.34) | |||||
| Book value | — | — | — | — | — | (2.13) | (6,841.57) | 84.44 | 9.98 | 0.78 | |||||
| Shares, m | — | — | — | — | — | 12 | 0 | 0 | 1 | 5 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | — | ||||
| P/S | — | — | — | — | — | 14.28 | 14.28 | 10.56 | 2.80 | — | |||||
| P/B | — | — | — | — | — | 0.00 | 0.00 | 2.49 | 0.28 | — | |||||
| EV/Sales | — | — | — | — | — | 28.82 | 28.82 | 7.98 | (5.04) | — | |||||
| EV/FCF | — | — | — | — | — | (1.05) | (1.05) | (0.71) | 0.28 | — | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | (8) | (8) | (7) | (10) | (11) | ||||
| Capex | — | — | — | — | — | (1) | 0 | 0 | 0 | 0 | |||||
| Free cash flow | — | — | — | — | — | (8) | (9) | (8) | (11) | (11) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | 7 | 2 | 1 | 4 | 2 | ||||
| Total debt | — | — | — | — | — | 35 | 7 | 0 | 0 | — | |||||
| Net debt | — | — | — | — | — | 27 | 3 | (2) | (5) | (2) | |||||
| Shareholders’ equity | — | — | — | — | — | (26) | (36) | 3 | 6 | 4 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | — | — | — | 0.00 | (154.87) | (205.80) | (143.78) | (176.93) | ||||
| ROIC | — | — | — | — | — | 0.00 | 0.00 | (407.29) | (595.10) | (395.49) | |||||
| ROE | — | — | — | — | — | 0.00 | 43.37 | 75.80 | (208.27) | (230.65) | |||||
Negative figures in brackets.
Fiscal years to Dec 2024 · latest quarter Jun 2024
Charts ten years each
Azitra, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| DRMA Dermata Therapeutics, Inc. | $4.5M | — (loss-making) | — | — | n/m | +9.99% (above 0%: growing) | 0.00% | 0.00% | Compare |
| ENLV Enlivex Ltd. | $4.5M | 0.0× | — | — | n/m | +35.94% (above 0%: growing) | 0.00% | 0.00% | Compare |
| NCNA NuCana PLC Sponsored ADR | $4.4M | — (loss-making) | — | — | n/m | +55.66% (above 0%: growing) | 0.00% | 0.00% | Compare |
| ADTX Aditxt, Inc. | $4.4M | — (loss-making) | — | +1,120.00% (above 0%: growing) | n/m | +60.82% (above 0%: growing) | 23.77% | (35,753.28%) | Compare |
| AZTR Azitra, Inc. | $4.3M | 1.0× | — (loss-making) | −93.38% (below 0%: shrinking) | n/m | −19.55% (below 0%: shrinking) | 100.00% | 0.00% | |
| LIMN Liminatus Pharma Inc. | $4.3M | — (loss-making) | — | — | n/m | +89.00% (above 0%: growing) | — | 0.00% | Compare |
| LNAI Lunai Bioworks Inc. | $4.2M | — (loss-making) | — | — | n/m | −1.65% (below 0%: shrinking) | 100.00% | (6,877.49%) | Compare |
| JUNS Jupiter Neurosciences, Inc. | $4.1M | — (loss-making) | — | — | n/m | −177.06% (below 0%: shrinking) | 87.19% | (11,334.30%) | Compare |
| OSRH OSR Health, Inc. | $4.1M | — (loss-making) | — | −72.20% (below 0%: shrinking) | n/m | −398.76% (below 0%: shrinking) | 27.43% | (960.69%) | Compare |
| Median of peers | $4.4M | — | — | — | — | +22.97% | 23.77% | (480.34%) |
Azitra, Inc. (AZTR) key facts
- Concern: Azitra, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $7,500.00, down 98.9% from fiscal 2023.
- Azitra, Inc. (AZTR) is a Biotechnology company in the Healthcare sector, listed on NYSE American.
- As of October 14, 2026, AZTR traded at $0.07, a market capitalization of $4.3 million.
- Return on equity was −230.7% and debt-to-equity 0.00.
- Its Piotroski F-score is 3 out of 9 and its Altman Z-score is −14.66 (distress zone) for fiscal 2024.